Protocol Ledger

NCT06500273 · Phase II · RECRUITING

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Interventional Phase II clinical trial protocol NCT06500273 sponsored by Allogene Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-18 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06500273
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06500273
Protocol FieldVerified Registry Value
NCT IdentifierNCT06500273
Consolidated Lead SponsorAllogene Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2024-06-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI